STOCK TITAN
  1. Home
  2. Sec-filings
  3. DMIIU
  4. [Form 4] Drugs Made In America Acquisition II Corp. Insider Trading Activity

[Form 4] Drugs Made In America Acquisition II Corp. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Drugs Made In America Acquisition II Corp. reported an insider transaction on a Form 4. Director Catherine Do acquired 100,000 ordinary shares on 09/26/2025 under transaction code J.

According to the footnote, the shares were acquired from the Issuer’s sponsor, Drugs Made In America Acquisition II LLC, for no consideration. Following the transaction, the reporting person beneficially owned 100,000 shares held in direct ownership.

Drugs Made In America Acquisition II Corp. ha segnalato una transazione interna su un modulo Form 4. La direttrice Catherine Do ha acquisito 100.000 azioni ordinarie in data 26/09/2025 con codice di transazione J.

Secondo la nota a piè di pagina, le azioni sono state acquisite dal sponsor dell'emittente, Drugs Made In America Acquisition II LLC, a nessun corrispettivo. A seguito della transazione, la persona che riporta ha beneficidamente detenuto 100.000 azioni in possesso diretto.

Drugs Made In America Acquisition II Corp. reportó una transacción de insider en un Form 4. La directora Catherine Do adquirió 100,000 acciones ordinarias el 26/09/2025 bajo el código de transacción J.

Según la nota al pie, las acciones fueron adquiridas del patrocinador de la Emisora, Drugs Made In America Acquisition II LLC, por ninguna contraprestación. Después de la transacción, la persona que reporta poseía beneficiosamente 100,000 acciones en propiedad directa.

Drugs Made In America Acquisition II Corp.는 Form 4에 내부자 거래를 보고했다. 이사 Catherine Do가 10만 주의 보통주를 2025-09-26에 거래 코드 J로 취득했다.

각주에 따르면, 이 주식은 발행기업의 스폰서인 Drugs Made In America Acquisition II LLC로부터 대가 없이 취득되었다. 거래 후 보고자는 직접 보유로 10만 주의 주식을 유익하게 소유했다.

Drugs Made In America Acquisition II Corp. a déclaré une transaction d’initié sur Formulaire 4. La directrice Catherine Do a acquis 100 000 actions ordinaires le 26/09/2025 sous le code de transaction J.

Selon la note, les actions ont été acquises auprès du sponsor de l’Émetteur, Drugs Made In America Acquisition II LLC, pour aucune contrepartie. Suite à la transaction, la personne déclarante détenait 100 000 actions en propriété directe.

Drugs Made In America Acquisition II Corp. meldete eine Insider-Transaktion auf Formular 4. Direktorin Catherine Do erwarb 100.000 Stammaktien am 26.09.2025 unter dem Transaktionscode J.

Laut der Fußnote wurden die Aktien vom Sponsor des Emittenten, Drugs Made In America Acquisition II LLC, ohne Gegenleistung erworben. Nach der Transaktion war die meldepflichtige Person mit 100.000 Aktien in direkter Eigentümerschaft wirtschaftlich berechtigt.

Drugs Made In America Acquisition II Corp. أبلغت عن معاملة داخلية في النموذج 4. المديرة Catherine Do اشترت 100,000 سهماً عاديّاً في 26/09/2025 تحت رمز المعاملة J.

وفق الهوامش، تم الحصول على الأسهم من راعي المُصدر، Drugs Made In America Acquisition II LLC, مقابل دون أي مقابل مالي. بعد المعاملة، امتلك الشخص المبلّغ عنه بشكل مستفيد 100,000 سهماً في ملك مباشر.

Drugs Made In America Acquisition II Corp. 在 Form 4 上披露了一起内幕交易。董事 Catherine Do 于 2025-09-26 以交易代码 J 购买了 100,000 股普通股。

根据脚注，这些股份是由发行人的赞助方 Drugs Made In America Acquisition II LLC 以 无对价 购买的。交易完成后，汇报人以 直接 持有的形式实际拥有 100,000 股股份。

Positive
  • None.
Negative
  • None.

Drugs Made In America Acquisition II Corp. ha segnalato una transazione interna su un modulo Form 4. La direttrice Catherine Do ha acquisito 100.000 azioni ordinarie in data 26/09/2025 con codice di transazione J.

Secondo la nota a piè di pagina, le azioni sono state acquisite dal sponsor dell'emittente, Drugs Made In America Acquisition II LLC, a nessun corrispettivo. A seguito della transazione, la persona che riporta ha beneficidamente detenuto 100.000 azioni in possesso diretto.

Drugs Made In America Acquisition II Corp. reportó una transacción de insider en un Form 4. La directora Catherine Do adquirió 100,000 acciones ordinarias el 26/09/2025 bajo el código de transacción J.

Según la nota al pie, las acciones fueron adquiridas del patrocinador de la Emisora, Drugs Made In America Acquisition II LLC, por ninguna contraprestación. Después de la transacción, la persona que reporta poseía beneficiosamente 100,000 acciones en propiedad directa.

Drugs Made In America Acquisition II Corp.는 Form 4에 내부자 거래를 보고했다. 이사 Catherine Do가 10만 주의 보통주를 2025-09-26에 거래 코드 J로 취득했다.

각주에 따르면, 이 주식은 발행기업의 스폰서인 Drugs Made In America Acquisition II LLC로부터 대가 없이 취득되었다. 거래 후 보고자는 직접 보유로 10만 주의 주식을 유익하게 소유했다.

Drugs Made In America Acquisition II Corp. a déclaré une transaction d’initié sur Formulaire 4. La directrice Catherine Do a acquis 100 000 actions ordinaires le 26/09/2025 sous le code de transaction J.

Selon la note, les actions ont été acquises auprès du sponsor de l’Émetteur, Drugs Made In America Acquisition II LLC, pour aucune contrepartie. Suite à la transaction, la personne déclarante détenait 100 000 actions en propriété directe.

Drugs Made In America Acquisition II Corp. meldete eine Insider-Transaktion auf Formular 4. Direktorin Catherine Do erwarb 100.000 Stammaktien am 26.09.2025 unter dem Transaktionscode J.

Laut der Fußnote wurden die Aktien vom Sponsor des Emittenten, Drugs Made In America Acquisition II LLC, ohne Gegenleistung erworben. Nach der Transaktion war die meldepflichtige Person mit 100.000 Aktien in direkter Eigentümerschaft wirtschaftlich berechtigt.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Do Catherine
(Last) (First) (Middle)
C/O DRUGS MADE IN AMERICA ACQU. II CORP.
1 EAST BROWARD BOULEVARD, SUITE 700
(Street)
FORT LAUDERDALE FL 33301
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Drugs Made In America Acquisition II Corp. [ DMII ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
09/26/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary shares 09/26/2025 J(1) 100,000 A (1) 100,000 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. As of the Transaction Date, the reporting person acquired 100,000 ordinary shares from Drugs Made In America Acquisition II LLC, the Issuer's sponsor, for no consideration.
/s/ Catherine Do 10/17/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did DMIIU report?

A director acquired 100,000 ordinary shares of Drugs Made In America Acquisition II Corp.

When did the DMIIU insider transaction occur?

The transaction date was 09/26/2025.

How many shares did the DMIIU director own after the transaction?

Beneficial ownership after the transaction was 100,000 shares.

What was the price paid for the shares in the DMIIU Form 4?

Per the footnote, the shares were acquired for no consideration.

What was the Form 4 transaction code for the DMIIU filing?

The transaction was coded J.

What is the reporting person’s relationship to DMIIU?

The reporting person is a Director of Drugs Made In America Acquisition II Corp.

Was the ownership direct or indirect after the DMIIU transaction?

The filing lists Direct (D) ownership.
Stock DMIIU logo
Drugs Made In America Acquisition II Corp.

NASDAQ:DMIIU

DMIIU Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

DMIIU Latest News

Sep 26, 2025
Drugs Made In America Acquisition II Corp. Announces Closing of $500,000,000 Initial Public Offering
Sep 25, 2025
Drugs Made In America Acquisition II Corp. Announces Pricing of $500,000,000 Initial Public Offering

DMIIU Stock Data

50.00M